That's important, since the method a protein in the body folds identifies if a pharmaceutical will be able to bind to that protein and work. In other words, we need to understand how these proteins fold if we desire a drug to work. Historically, this has been an experimental procedure (diplomatic relations). Now, Alpha, Fold can forecast protein folding with 92. 4% precision. That's going to make it much simpler to produce drugs that do what they're developed to do. This was a development practically nobody observed. But it's going to have extensive implications for treating illness. I anticipate that Alpha, Fold will be 98% precise by the end of 2021.
And, obviously, there will be plenty of financial investment opportunities in this area, too. Shifting topics It's going to be a good year for bitcoin. I'm bullish on it in 2021 (second wave). That said, I still believe bitcoin will continue to be unpredictable. We're close to all-time highs. I wouldn't be shocked if it pulled back maybe significantly before going greater - jeff brown 2021 stock picks. I've been covering bitcoin for a long time now. One of the very first research study reports I ever published was on bitcoin. That remained in June 2015. At the time, bitcoin was trading for about $240. Bitcoin trades for over $34,000 today.
But at the time of that initial suggestion, I entitled my report "What's the Big Deal With Bitcoin?" That shows you where the conversation was at the time. We were mainly educating readers. But that's not the big concern anymore. Now we're seeing institutional cash finally take an interest in bitcoin. Massachusetts Mutual Life Insurance took a $100 million stake in bitcoin in December. This is not some small, niche business. Mass, Mutual is a relied on 170-year-old organization. So think of that. In five years, we went from informing readers on what bitcoin is to a business like Mass, Mutual taking a $100 million stake.
Which's a big factor I'm bullish on it this year. jeff brown biotech genome sequencing. Regards, Jeff Brown, Editor, The Bleeding Edge I have a bonus prediction 2020 was a record year for IPOs. 552 U.S. companies went public the most in more than twenty years. These companies raised a total of $172 billion. That's an all-time high beating the previous annual record by 43%. I predict 2021 will be another record year in IPOs. There are numerous excellent personal business on the verge of hitting the general public markets And I have actually been working on a new method for you to invest even prior to these companies go public.
This chance has actually been building over the last few years. I can't wait to tell you everything about it. Join me tomorrow at 8 p. m. ET for my Pre-IPO Code Event to learn all the details. Go right here to schedule your area free of charge.
Emma Walsh here, handling editor of the Diary. Routine Journal readers know that tech isn't our typical beat (jeff brown biotech stock pick for 2020). And when it concerns tech investing, we leave it to the experts. Fortunately, we have a number of such specialists in our Rolodex. Our coworker Jeff Brown will be familiar to our longtime readers. He is one of the most accomplished tech investing professionals we understand (artificial intelligence). In fact, he had several triple-digit returns in his Brownstone Research study portfolios last year. Here's what Jeff thinks the tech sector will bring us in 2021 Each year, I like to take a look at the huge photo and anticipate what's simply around the corner.
That includes things like 5G networks, biotech, expert system, and a lot more. These trends are experiencing exponential development and developing amazing opportunities for investors. I want to ensure all our readers are gotten ready for what's next. And with that in mind, let me draw the image of what I see coming in the next 12 months Our new 5G (fifth-generation) wireless networks are a topic I've been covering for years now. diplomatic relations. However in spite of what lots of readers may believe, this is a pattern that's simply starting. Despite the fact that the COVID-19 pandemic interfered with supply chains last year, a remarkable 250 million 5G-enabled devices were still offered.
And all of this eventually resulted in Apple delaying the release of the 5G-enabled i, Phone 12 by two months (jeff brown biotech stock). Losing two months of manufacturing and sales really impacts how numerous 5G devices are sold in the fiscal year. When you consider all of that, selling 250 million systems is remarkable. More notably, the delays triggered by the pandemic developed a heap of suppressed demand. And that demand is now going to be pushed into 2021. In fact, I predict that more than 500 million 5G devices will be delivered in 2021 - korean actress. Which's not my only 5G forecast When I've discussed 5G in the past, I have actually described its three various stages.
In Stage Two, 5G devices go on sale. 5G phones and other items begin to reach customers. And in Phase 3, 5G services begin to be provided (toxic tech 5 tech darlings). That's when we start to see applications working on 5G networks. Consider things like massive multiplayer video games over a smart phone. That's not possible with 4G. It will be with 5G. And my second 5G forecast for 2021 is that we will begin Phase Three by this summer. This starts something of a virtuous cycle: The majority of people don't truly care about the innovation. However they will care if there are amazing applications that can just be accessed with a 5G phone.
That causes more 5G apps being developed. In reality, 5G is going to open a suite of extraordinary applications: self-driving automobiles, the Internet of Things, robotic surgical treatment, and more. All of these innovations require 5G. The financial investment chances going forward will be huge. Stepping away from 5G, the next essential technology I anticipate in 2021 is CRISPR hereditary editing. CRISPR means "clustered frequently interspaced short palindromic repeat." It's a mouthful. However it is among the most exciting advancements in biotechnology. At a high level, CRISPR is a technology that can modify our genetic makeup as if it were software application.
The program can crash or not operate properly. CRISPR uses a similar idea however with our genetic code. "Typos" in our genome can cause illness. CRISPR can fix these "typos." For several years, CRISPR was mainly a niche innovation that wasn't well understood. And throughout that time, there were actually just three companies operating in this space. However things are altering. CRISPR is no longer just theoretical. We're seeing actual results. We're treating illness and seeing that this innovation simply works. And as an outcome, a "2nd crop" of early-stage CRISPR business is going public and delivering unbelievable returns. This whole industry is efficiently a greenfield opportunity.
There's space for lots of companies to exist in this area. melania trump. And there will be more. That's my forecast for CRISPR in 2021. I predict that 2 or 3 more hereditary editing companies will hold their IPOs. Sticking to biotechnology, we are seeing incredible things taking place at the convergence of biotech and expert system (AI). Google's AI subsidiary, Deep, Mind, just revealed at the end of 2020 that its newest Alpha, Fold software application can accurately predict the folding of a protein based entirely on its amino acid series with 92. 4% precision. That's essential since the method a protein in the human body folds identifies if a pharmaceutical will be able to bind to that protein and work.
Historically, this has actually been a trial-and-error procedure. And now, Alpha, Fold can predict protein folding with 92. 4% precision. That's going to make it much simpler to create drugs that do what they're created to do. And here's my next forecast. I predict that Alpha, Fold will be 98% precise by the end of 2021. And we will see not simply one but a number of drug treatments produced using this technology. This was among those breakthroughs that nearly nobody discovered. But it's going to have profound implications for treating disease. And, naturally, there will be plenty of investment chances in this area, too.
It's going to be an excellent year for bitcoin. I'm bullish on it in 2021. That stated, I still think bitcoin will continue to be unstable. We're close to all-time highs. I wouldn't be surprised if it pulled back maybe significantly prior to going higher. I've been covering bitcoin for a long period of time now. Among the first research study reports I ever published was on bitcoin - jeff brown top biotech stock 2021. That remained in June 2015. At the time, bitcoin was trading for about $240. Bitcoin trades for over $40,000 today. So that's a 16,500%+ return on investment for any person who followed my recommendation. But at the time of that initial recommendation, I titled my report, "What's the Big Offer With Bitcoin?" That shows you where the conversation was at the time.
However nobody is asking that concern any longer. Now, we're seeing institutional cash finally taking an interest in bitcoin. The big news was that Massachusetts Mutual Life Insurance coverage took a $100 million stake in bitcoin in December. This is not some small, specific niche enterprise. jeff brown investor prediction. Mass, Mutual is a 150-year-old institution. So think about that. In 5 years, we went from educating readers on what bitcoin is to a company like Mass, Mutual taking a $100 million stake. The institutional adoption of bitcoin will continue. Which's a big reason that I'm bullish on it this year. Regards, Jeff Brown, Editor, The Bleeding Edge I have another bonus prediction In 2021, we're going to have another record year in IPOs. One website reports that Jeff Brown is worth about $27. 5 million and claims the information is up to date as of February 2021, however we might not separately validate this claim. Offered Jeff Brown's past, he likely has a considerable net worth, but we can't hammer down an exact figure at this minute. Brown is best known for his sage-like ability to choose winning innovation stocks. He invested more than 25 years investigating innovation business like Qualcomm, NXP semiconductors, and Juniper Networks. Brown's substantial experience gives him an outstanding point of view on the marketplace. He's always on the hunt for brand-new opportunities, and he shares a lot of his best choices in the Near Future Report.
That's high appreciation, but it's not absurdly reasoned. Brown has an exceptional track record as a stock-picker, and he effectively anticipated a few of the most significant financial occasions of the previous twenty years. Although he doesn't appear to launch his choices to the public, the service's success is a direct indication of Brown's stock-picking expertise. No one on Wall Street gets it right every time, but Jeff Brown's precise forecasts have earned him legions of devoted followers. That says a lot about his capability. The Future Report is released by Brownstone Research, a popular financial research study publisher. Brownstone Research provides several research services with a large range of expertises - exponential tech investor.
The business is also associated with Bonner & Partners, another well-respected research publisher - self-driving cars. On its site, Brownstone states its objective is to offer retail investors with professional-grade research study: "For too long, the best investment research has actually not been readily available to specific financiers. It has been usually booked for financial investment banks, hedge funds, personal equity, and high-net-worth customers. jeff brown biotech stock. The objective of Brownstone Research study is to make that kind of exclusive research available to any financiers aiming to gain an edge in the markets. The goal is basic to deliver distinct and rewarding investment research found nowhere else." -Brownstone Research study website excerpt from the Jeff Brown is the founder of Brownstone Research, and he likewise works as the company's Chief Financial investment Expert.
With Brown guiding the ship, Brownstone Research is a powerhouse publisher with lots to use its customers. After decades of stable success at the helm of top-tier business like Tesla and Space, X, Elon Musk is a home name throughout the majority of America. If you know even a bit about the market, you understand that he has a reputation as a King Midas of sorts. brownstone research stock. Everything he touches relies on gold! Jeff is well aware of Elon Musk's executive prowess, so he constantly has an eye out for the Silicon Valley rock star's next relocation. This time, Jeff has an early lead on Elon's next big job.
In fact, Brown thinks S.A.V. jeff brown 1 biotech company. might be "the most significant trend of the 2020s, and he's not alone. Have a look at these quotes from other widely known S.A.V. bulls: Elon's next big act will be marrying 2 innovative innovations: synthetic intelligence and electric automobiles. Musk hopes the mix will assist him develop the very first fully-autonomous, self-driving cars and trucks ever. It's nothing brief of the vehicle industry's Holy Grail. As you know, electric vehicles and self-driving automobile stocks have been big this year, but the Wall Street machine has actually approved buzz without much tangible outcome. Regardless of an extreme boost in competition over the past few years, Brown still believes Musk has the very best chance of putting everything together.
tech might be the magic string that ties all of it together. S.A.V. means Shared Autonomous Car, and it could be the future of transport. Basically, this technology would permit you to lease your cars and truck as a self-governing, self-driving taxi when you're not utilizing it. You simply leave the car and press a button on an app that informs the car to "join the fleet." Next thing you know, you're relaxing on your sofa while your car shuttles ride-sharers around town. Most importantly, you get to keep a hefty chunk of the profits. It sounds outrageous, however it could be closed than you think.